AbbVie (ABBV) vs Johnson & Johnson (JNJ): Diverging Momentum in Healthcare Stocks
Key Takeaways
- Both ABBV and JNJ have posted strong year-to-date gains, yet their recent market momentum is diverging sharply.
- AbbVie's relative performance is being driven by immunology growth and pipeline catalysts, while Johnson & Johnson faces a slowing medical device (MedTech) segment and a large talc litigation charge.
- ABBV trades at a much higher trailing price-to-earnings (P/E) multiple, while JNJ carries a lower valuation and a higher dividend yield.
- Johnson & Johnson's pharmaceutical arm is thriving, but its MedTech business is decelerating and weighing on overall sentiment.
- Investors weighing growth momentum may favor AbbVie, while income-focused investors may find Johnson & Johnson's stability and yield more compelling.
Setting the Stage for Two Healthcare Leaders
AbbVie and Johnson & Johnson stand among the largest names in global healthcare, yet they present investors with distinctly different profiles. This comparison looks at how their business models, growth drivers, recent positioning, and risk factors align in the current environment. AbbVie operates as a focused biopharmaceutical company centered on immunology, oncology, and neuroscience, while Johnson & Johnson functions as a diversified healthcare group with exposure across pharmaceuticals and medical devices. From what I see, this side-by-side view offers a useful reference for traders monitoring momentum as well as longer-term investors assessing stability and income potential.
AbbVie's Recent Performance and Pipeline Momentum
AbbVie concentrates on research-driven biopharmaceuticals in immunology, oncology, neuroscience, and aesthetics. The stock has recently traded near the upper end of its 52-week range, supported by sustained gains from newer immunology products such as Skyrizi and Rinvoq. Management has noted that losses from the patent expiration of Humira have been more than offset by growth across these platforms. I also checked this using Tickeron’s AI Pattern Search Engine to confirm the trend consistency. Recent developments include two FDA Breakthrough Therapy Designations for the investigational cancer drug telisotuzumab adizutecan (Temab-A) in colorectal and lung cancer. The company raised full-year revenue guidance after a solid first quarter, though it made a modest adjustment to its adjusted earnings outlook related to the pending Apogee Therapeutics acquisition. Sentiment stays generally positive, even as the elevated trailing P/E multiple and some insider selling have sparked valuation discussions.
Johnson & Johnson's Recent Results and Segment Dynamics
Johnson & Johnson runs two main segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). The stock pulled back following its latest quarterly report despite beating expectations and raising full-year guidance. The reaction stemmed primarily from a slowdown in MedTech growth and a sizable one-time charge connected to a proposed resolution of ovarian talc litigation. In pharmaceuticals, growth has remained robust, led by products including Tremfya, Darzalex, Caplyta, and Spravato, which help counter declining revenue from Stelara amid biosimilar competition. MedTech growth has slowed across recent quarters due to factors such as Middle East disruptions, European budget constraints, pricing pressure in China, and softer demand for Abiomed heart pumps. Management has signaled it is considering a spinoff of its orthopedics business, which could refine focus but introduces near-term uncertainty.
Head-to-Head Comparison of Key Factors
The main contrast between the two companies centers on diversification and growth composition. Johnson & Johnson's broad exposure across pharmaceuticals and medical devices has historically provided balance, but that balance now appears to work against it as MedTech decelerates. AbbVie, more concentrated by comparison, currently benefits from a focused and high-momentum immunology franchise. On valuation, the difference is notable: AbbVie's trailing P/E sits elevated relative to its history, reflecting optimism around its pipeline, whereas Johnson & Johnson trades at a lower multiple and offers a higher dividend yield. Growth drivers also vary, with AbbVie relying on Skyrizi, Rinvoq, and a strong late-stage pipeline, while Johnson & Johnson depends on oncology and immunology drugs to offset biosimilar erosion in Stelara. Risk profiles differ as well, with AbbVie facing pipeline execution and competitive pressures, and Johnson & Johnson contending with litigation overhangs, MedTech headwinds, and potential restructuring costs. Market sentiment shows AbbVie's trend holding steadier, while Johnson & Johnson's pullback has added near-term uncertainty.
Exploring Automated Trading Strategies
When comparing stocks like these, I often review Tickeron’s Trending AI Robots to identify automated strategies aligned with current conditions. The platform hosts hundreds of AI Trading Bots that trade thousands of tickers, each with distinct styles, timeframes, and performance data. This curated selection helps surface the most relevant approaches for prevailing market environments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
JNJ in downward trend: 10-day moving average crossed below 50-day moving average on October 05, 2026
The 10-day moving average for JNJ crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 59%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on JNJ as a result. In 33 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 40%.
The Moving Average Convergence Divergence Histogram (MACD) for JNJ turned negative on September 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 20 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 43%.
JNJ moved below its 50-day moving average on September 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 40%.
The Aroon Indicator for JNJ entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where JNJ's RSI Indicator exited the oversold zone, 12 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 41%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 27 of 50 cases where JNJ's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 54%.
Following a +2.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 164 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
JNJ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 6 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.710) is normal, around the industry mean (19.199). P/E Ratio (31.549) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.019) settles around the average of (0.025) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an investment holding company with interests in health care products
Industry PharmaceuticalsMajor
Advertisement